PT - JOURNAL ARTICLE AU - Z. Peng AU - J. L. Jimenez TI - Exhaled CO<sub>2</sub> as COVID-19 infection risk proxy for different indoor environments and activities AID - 10.1101/2020.09.09.20191676 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.09.20191676 4099 - http://medrxiv.org/content/early/2020/09/10/2020.09.09.20191676.short 4100 - http://medrxiv.org/content/early/2020/09/10/2020.09.09.20191676.full AB - CO2 is co-exhaled with aerosols containing SARS-CoV-2 by COVID-19 infected people and can be used as a proxy of SARS-CoV-2 concentrations indoors. Indoor CO2 measurements by low-cost sensors hold promise for mass monitoring of indoor aerosol transmission risk for COVID-19 and other respiratory diseases. We derive analytical expressions of CO2-based risk proxies and apply them to various typical indoor environments. Contrary to some earlier recommendations setting a single indoor CO2 threshold, we show that the CO2 level corresponding to a given infection risk varies by over 2 orders of magnitude for different environments and activities. Although large uncertainties, mainly from virus exhalation rates, are still associated with our infection risk estimates, our study provides more specific and practical recommendations for low-cost CO2-based indoor infection risk monitoring.One Sentence Summary Guidelines for indoor CO2 concentrations to reduce indoor COVID-19 infection risk need to account for environment and activity types.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is a modeling study. Data were computationally generated.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the main text or the supplementary materials. The COVID-19 Aerosol Transmission Estimator, with which a large part of calculations in this study were done, is freely available at https://tinyurl.com/covid-estimator.